Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 19

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 19
---
 under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable 
           third-party costs as well as milestones and royalties on product sales. Receivables are recorded for product sales under the French AC and commercial sales of MIPLYFFA and OLPRUVA to a single specialty pharmacy. The Company provides reserves against receivables for estimated losses that 
            may result from a customer's inability to pay. Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company’s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve. 

             Accounts and other receivables consist of the following (in thousands):

              March 31,  December 31, 
   2025    2024  
 Commercial accounts receivable  $6,861  $4,010 
 Receivables related to product reimbursements   4,555   5,380 
 Royalties and milestones accounts receivable   987   786 
 Other receivables   214   333 
 Total receivables  $12,617  $10,509 

            As of
            March 31, 2025
           , and 
            December 31, 2024
           ,
            no reserve or allowance for doubtful accounts had been established.

   G.Stock and Warrants

   Authorized, Issued, and Outstanding Common Shares
    
   As of  March 31, 2025, and  December 31, 2024, the Company had authorized shares of common stock of 250,000,000 shares. Of the authorized shares, 56,255,055 and 55,246,401 shares of common stock were issued as of  March 31, 2025, and  December 31, 2024, respectively, and 54,679,363 and 53,670,709 shares of common stock were outstanding as of  March 31, 2025, and  December 31, 2024, respectively.
    
   As of  March 31, 2025, and  December 31, 2024, the Company had reserved authorized shares of common stock for future issuance as follows: